|
Active substance |
Isatuximab |
|
Holder |
Sanofi Belgium |
|
Status |
Closed |
|
Indication |
in combination with carfilzomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and being lenalidomide exposed/refractory. |
|
Public documents |
|
|
Last update |
29/09/2023 |
Sarclisa
Last updated on 23/04/2024